Jaguar Health, Inc. SEC filings JAGX
Jaguar Health, Inc. has 1,004 filings in SEC EDGAR's recent list, going back to Jun 16, 2016. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 19, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 29, 2026 | — |
| DEF 14A | Proxy statement | Oct 8, 2026 | Nov 6, 2026 |
| PRE 14A | Preliminary proxy statement | Sep 18, 2026 | Oct 23, 2026 |
| DEF 14A | Proxy statement | Aug 3, 2026 | Sep 4, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 24, 2026 | Sep 4, 2026 |
| DEFA14A | Additional proxy material | May 29, 2026 | — |
| DEFA14A | Additional proxy material | May 6, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | May 22, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2026 | May 22, 2026 |
| DEF 14A | Proxy statement | Mar 24, 2026 | Apr 20, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 13, 2026 | Apr 20, 2026 |
| DEF 14A | Proxy statement | Nov 10, 2025 | Dec 8, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 28, 2025 | Dec 8, 2025 |
| DEFA14A | Additional proxy material | Aug 6, 2025 | — |
| DEF 14A | Proxy statement | Jul 21, 2025 | Aug 19, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 11, 2025 | Aug 19, 2025 |
| DEF 14A | Proxy statement | Feb 24, 2025 | Mar 13, 2025 |
| PRE 14A | Preliminary proxy statement | Feb 14, 2025 | Mar 13, 2025 |
| DEFA14A | Additional proxy material | May 31, 2024 | — |
| DEF 14A | Proxy statement | May 21, 2024 | Jun 21, 2024 |
| PRE 14A | Preliminary proxy statement | May 10, 2024 | Jun 21, 2024 |
| DEF 14A | Proxy statement | Mar 15, 2024 | Apr 9, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 5, 2024 | Mar 4, 2024 |
| DEF 14A | Proxy statement | May 31, 2023 | Jul 7, 2023 |
| PRE 14A | Preliminary proxy statement | May 16, 2023 | Jul 7, 2023 |
| DEF 14A | Proxy statement | Nov 28, 2022 | Jan 20, 2023 |
| PRE 14A | Preliminary proxy statement | Nov 18, 2022 | Jan 20, 2023 |
| DEF 14A | Proxy statement | Aug 29, 2022 | Sep 30, 2022 |
| PRE 14A | Preliminary proxy statement | Aug 19, 2022 | Sep 30, 2022 |
| DEFA14A | Additional proxy material | May 23, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 10, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2022 | Jun 10, 2022 |
| DEFA14A | Additional proxy material | Aug 24, 2021 | — |
| DEFA14A | Additional proxy material | Aug 19, 2021 | — |
| DEFA14A | Additional proxy material | Aug 19, 2021 | — |
| DEFA14A | Additional proxy material | Aug 18, 2021 | — |
| DEFA14A | Additional proxy material | Aug 18, 2021 | — |
| DEFA14A | Additional proxy material | Jul 23, 2021 | — |
| DEFA14A | Additional proxy material | Jun 8, 2021 | — |
| DEFA14A | Additional proxy material | May 20, 2021 | — |
| DEFA14A | Additional proxy material | May 17, 2021 | — |
| DEFA14A | Additional proxy material | May 14, 2021 | — |
| DEF 14A | Proxy statement | Apr 13, 2021 | May 13, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2021 | May 13, 2021 |
| DEFA14A | Additional proxy material | Dec 17, 2020 | — |
| DEFA14A | Additional proxy material | Dec 10, 2020 | — |
| DEFA14A | Additional proxy material | Dec 4, 2020 | — |
| DEF 14A | Proxy statement | Nov 6, 2020 | Dec 9, 2020 |
| PRE 14A | Preliminary proxy statement | Oct 22, 2020 | Dec 9, 2020 |
| DEFA14A | Additional proxy material | Jun 25, 2020 | — |
| DEF 14A | Proxy statement | Jun 19, 2020 | Jul 21, 2020 |
| PRE 14A | Preliminary proxy statement | Jun 9, 2020 | Jul 21, 2020 |
| DEF 14A | Proxy statement | Apr 13, 2020 | May 15, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2020 | May 15, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 29, 2019 | May 24, 2019 |
| PRE 14A | Preliminary proxy statement | Mar 22, 2019 | Apr 29, 2019 |
| DEF 14A | Proxy statement | Jan 18, 2019 | Feb 25, 2019 |
| PRE 14A | Preliminary proxy statement | Jan 8, 2019 | Feb 25, 2019 |
| DEF 14A | Proxy statement | Apr 24, 2018 | May 18, 2018 |
| DEFA14A | Additional proxy material | Apr 24, 2018 | — |
| PRE 14A | Preliminary proxy statement | Apr 13, 2018 | May 18, 2018 |
| DEF 14A | Proxy statement | Feb 15, 2018 | Mar 12, 2018 |
| PRE 14A | Preliminary proxy statement | Feb 6, 2018 | Mar 12, 2018 |
| DEF 14A | Proxy statement | Nov 20, 2017 | Dec 1, 2017 |
| PRE 14A | Preliminary proxy statement | Nov 7, 2017 | Dec 1, 2017 |
| DEFA14A | Additional proxy material | Apr 17, 2017 | — |
| DEF 14A | Proxy statement | Apr 17, 2017 | May 8, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2017 | May 8, 2017 |
Showing 69 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JAGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1585608
- Former names
- Jaguar Animal Health, Inc. (until Jul 31, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.